Portal de investigación
Análisis de la Persistencia y Adherencia de terapia biológica en pacientes con psoriasis grave de la Comunidad Valenciana (DERMA-FARMA 01).
Datos básicos
- Código:
- DERMA-FARMA 01
- Protocolo:
- DERMA-FARMA 01
- EUDRACT:
- NCT:
- Centro:
- ESPECIALIZADA Y PRIMARIA L´HORTA MANISES S.A.
- Dotación:
- Año de incio:
- 2022
- Año de finalización:
- 2023
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
GENERALITAT VALENCIANA
Resultados del Ensayo Clínico
[Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Minano Medrano, R.; (...); Garcia-Doval, I
Article. 10.1016/j.ad.2022.01.035. 2022
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
Daudén E; (...); Llamas-Velasco M
Article. 10.1111/ijd.16915. 2024
Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer -Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Miñano Medrano R; (...); García-Doval I
Article. 10.1016/j.ad.2022.01.003. 2022
Safety and Efficacy Profile of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis: An 18-Patient Case Series.
Melgosa Ramos, F J; (...); Martorell, A
Article. 10.1016/j.ad.2024.08.009. 2024